New hope for kids with kidney disease: rituximab cuts relapse risk
NCT ID NCT07049172
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether rituximab, a medication that targets certain immune cells, could help children with a challenging form of nephrotic syndrome (a kidney disease) that keeps coming back. 91 children were split into two groups: one received rituximab plus special nursing care, the other received a standard drug (tacrolimus) plus the same care. The goal was to see which approach better prevented relapses and improved quality of life over 6 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
91 people
The number who actually took part.
- Started
-
Jan 2021
- Finished
-
Dec 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 to 15 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of primary pediatric nephrotic syndrome, specifically steroid-dependent nephrotic syndrome (SDNS) or frequently relapsing nephrotic syndrome (FRNS), as defined by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. (SDNS is defined as relapse occurring during tapering of glucocorticoids or within 14 days of discontinuation; FRNS is defined as ≥2 relapses within 6 months of initial response or ≥4 relapses in any 12-month period). * Age between 6 and 15 years. * Normal intellectual development and the ability to understand and communicate. * Informed consent obtained from the guardians and assent from children capable of understanding. Exclusion Criteria: * Steroid-resistant nephrotic syndrome (SRNS). * Severe renal insufficiency (according to KDIGO criteria or other relevant standards). * Cognitive or mental disorders. * Worsening condition upon admission necessitating intensive care. * Parents unable to provide long-term care or unwilling to participate. * Interruption of hospitalization for any reason. * Prior treatment with rituximab or tacrolimus. * Co-existing significant kidney, urinary system diseases (other than NS), or severe active urinary tract infection. * Significant liver function impairment. * Known hypersensitivity to rituximab or tacrolimus.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Nephrotic syndrome in children are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wuhan Children's Hospital
Wuhan, Hubei, 430015, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could less steroid be just as good for kids with kidney disease?
- Ear-Zap therapy could spare kids from harsh kidney drugs
- Ear-Zap therapy could spare kids from steroid side effects
- Personalized trial matching could revolutionize kidney disease treatment
- New hope for kids with kidney disease: can dupilumab stop relapses?
- New study aims to measure swelling in kidney disease patients